IMNN-001

BIOLOGICAL3 trials

Sponsors

Imunon

Conditions

Epithelial Ovarian CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Phase 1

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

CompletedNCT02480374

ImunonEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2015-09-30End: 2017-05-31Updated: 2024-10-02

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Active, not recruitingNCT03393884

ImunonEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2018-09-05End: 2026-05-30Target: 130Updated: 2026-05-04

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

RecruitingNCT05739981

ImunonFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2023-02-10End: 2028-08-30Target: 30Updated: 2026-09-15

Related Papers

A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.

Journal of Clinical Oncology2025-05-281 citations

A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC).

Journal of Clinical Oncology2024-06-01

Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial

JCO Clinical Cancer Informatics2023-01-0111 citations

Abstract 1025: Phase Ib trial single-arm efficacy estimates via comparison to a historical clinical trial synthetic control arm

Cancer Research2022-06-15

Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer.

Journal of Clinical Oncology2019-03-106 citations

Abstract A76: Immunologic changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemo in newly diagnosed advanced stage ovarian cancer patients

Clinical Cancer Research2018-08-01

Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.

Journal of Clinical Oncology2017-05-201 citations

Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.

Journal of Clinical Oncology2017-03-013 citations

Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.

Journal of Clinical Oncology2017-03-01

Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Journal of Clinical Oncology2016-05-202 citations